Apr 11 |
This MiNK Therapeutics Insider Increased Their Holding In The Last Year
|
Apr 8 |
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
|
Mar 22 |
MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
|
Mar 22 |
Q4 2023 Mink Therapeutics Inc Earnings Call
|
Mar 21 |
MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript
|
Mar 21 |
MiNK Therapeutics GAAP EPS of -$0.16 misses by $0.01
|
Mar 21 |
MiNK Reports Fourth Quarter and Year-End 2023 Results
|
Feb 6 |
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
|
Jan 30 |
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
|
Dec 20 |
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
|